Glucagon and GLP-1 receptor co-agonist
Survodutide 2.4 mg subcutaneous once weekly
SURV_SC_2p4MG_QW
Related
- All doses pooled: Survodutide injection
- Survodutide 0.3 mg subcutaneous once weekly
- Survodutide 0.9 mg subcutaneous once weekly
- Survodutide 1.8 mg subcutaneous once weekly
- Survodutide 2.7 mg subcutaneous once weekly
- Survodutide 1.2 mg injection
- Survodutide 1.8 mg injection
- Survodutide 6.0 mg subcutaneous once weekly
- Survodutide 0.6 mg subcutaneous once weekly
- Survodutide 3.6 mg subcutaneous once weekly
- Survodutide 4.8 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -9.35 (-13.92 to -3.95) | 0.44 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.75 (1.68 to 32.20) | 0.67 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 10.73 (2.23 to 34.74) | 0.64 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 6.81 (1.68 to 24.36) | 0.49 |